CR9266A - Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos - Google Patents

Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Info

Publication number: CR9266A
Authority: CR; Costa Rica
Prior art keywords: glucagon; compositions; methods; similar; peptide agonists
Prior art date: 2004-12-22

Application number

CR9266A

Other languages

English (en)

Inventor

T O'neil Karyn

O'neil John

Picha Kristen

Xu Gang

Lark Michael

Original Assignee

Centocor Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-12-22

Filing date

2007-07-20

Publication date

2008-09-09

2007-07-20 Application filed by Centocor Inc filed Critical Centocor Inc

2008-09-09 Publication of CR9266A publication Critical patent/CR9266A/es

Links

102000051325 Glucagon Human genes 0.000 title 1
108060003199 Glucagon Proteins 0.000 title 1
239000000556 agonist Substances 0.000 title 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
229960004666 glucagon Drugs 0.000 title 1
239000000203 mixture Substances 0.000 title 1
108090000765 processed proteins & peptides Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/575—Hormones
- G01N2333/605—Glucagons
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Public Health (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Zoology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Toxicology (AREA)
Analytical Chemistry (AREA)
Obesity (AREA)
Emergency Medicine (AREA)

CR9266A 2004-12-22 2007-07-20 Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos CR9266A (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US63831304P	2004-12-22	2004-12-22

Publications (1)

Publication Number	Publication Date
CR9266A true CR9266A (es)	2008-09-09

Family

ID=37962937

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CR9266A CR9266A (es)	2004-12-22	2007-07-20	Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos

Country Status (17)

Country	Link
US (1)	US20070128193A1 (es)
EP (1)	EP1843788A4 (es)
JP (1)	JP2008525477A (es)
KR (1)	KR20070090036A (es)
CN (1)	CN101415439A (es)
AU (1)	AU2005337493A1 (es)
BR (1)	BRPI0519241A2 (es)
CA (1)	CA2592065A1 (es)
CR (1)	CR9266A (es)
EA (1)	EA200701362A1 (es)
IL (1)	IL183940A0 (es)
MX (1)	MX2007007602A (es)
NI (1)	NI200700158A (es)
NO (1)	NO20073814L (es)
SG (1)	SG158158A1 (es)
WO (1)	WO2007046834A2 (es)
ZA (1)	ZA200706030B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9006175B2 (en)	1999-06-29	2015-04-14	Mannkind Corporation	Potentiation of glucose elimination
EP1494732B1 (en)	2002-03-20	2008-01-30	MannKind Corporation	Inhalation apparatus
DK1786784T3 (da)	2004-08-20	2011-02-14	Mannkind Corp	Katalyse af diketopiperazinsyntese
CN104436170B (zh)	2004-08-23	2018-02-23	曼金德公司	用于药物输送的二酮哌嗪盐
WO2006111169A1 (en) *	2005-04-21	2006-10-26	Gastrotech Pharma A/S	Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
AU2006290227B2 (en)	2005-09-14	2012-08-02	Mannkind Corporation	Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
WO2007081654A2 (en) *	2005-12-28	2007-07-19	Zoltan Laboratories Llc	Compositions and methods to enhance viability and function of islet cells
KR20080096809A (ko)	2006-02-22	2008-11-03	맨카인드 코포레이션	디케토피페라진 및 활성제를 포함하는 마이크로입자의 약학특성의 개선 방법
TW200843794A (en) *	2006-12-21	2008-11-16	Centocor Inc	Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
WO2008092209A1 (en) *	2007-02-01	2008-08-07	Arana Therapeutics Limited	Protein construct with improved properties
SG10201507036TA (en) *	2008-06-13	2015-10-29	Mannkind Corp	A dry powder inhaler and system for drug delivery
US8485180B2 (en)	2008-06-13	2013-07-16	Mannkind Corporation	Dry powder drug delivery system
EP2609954B1 (en)	2008-06-20	2021-12-29	MannKind Corporation	An interactive apparatus for real-time profiling of inhalation efforts
TWI614024B (zh)	2008-08-11	2018-02-11	曼凱公司	超快起作用胰島素之用途
MX2011003277A (es) *	2008-10-14	2012-09-21	Salubrious Pharmaceuticals LLC	Proceso para el tratamiento de la artritis reumatoide, temblores/enfermedad de parkinson, esclerosis multiple y cancer de tipo no viral.
PT3228320T (pt)	2008-10-17	2020-03-26	Sanofi Aventis Deutschland	Combinação de uma insulina e de um agonista do glp-1
DK2373681T3 (en)	2008-12-10	2017-04-24	Glaxosmithkline Llc	PHARMACEUTICAL COMPOSITIONS OF ALBIGLUTID
US8314106B2 (en)	2008-12-29	2012-11-20	Mannkind Corporation	Substituted diketopiperazine analogs for use as drug delivery agents
MX2011009512A (es)	2009-03-11	2011-11-29	Mannkind Corp	Aparato, sistema y metodo para medir la resistencia de un inhalador.
MY157166A (en)	2009-06-12	2016-05-13	Mankind Corp	Diketopiperazine microparticles with defined specific surface areas
KR101853606B1 (ko)	2009-07-06	2018-05-03	사노피-아벤티스 도이칠란트 게엠베하	메티오닌을 함유하는 수성 인슐린 제제
CA2778698A1 (en)	2009-11-03	2011-05-12	Mannkind Corporation	An apparatus and method for simulating inhalation efforts
DK2498802T3 (en)	2009-11-13	2015-04-13	Sanofi Aventis Deutschland	Pharmaceutical composition comprising a GLP-1 agonist, insulin and a methionine
KR101337322B1 (ko)	2009-11-13	2013-12-06	사노피-아벤티스 도이칠란트 게엠베하	Ｇｌｐ-1 효능제 및 메티오닌을 포함하는 약제학적 조성물
JP2013525491A (ja)	2010-05-04	2013-06-20	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	心血管障害を治療または予防し心血管保護を提供する方法
CA2797095A1 (en)	2010-05-13	2011-11-17	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
AU2011202239C1 (en)	2010-05-19	2017-03-16	Sanofi	Long-acting formulations of insulins
IL223742A (en)	2010-06-21	2016-06-30	Mannkind Corp	A dry powder inhaler and preparation for it
MX2012014576A (es)	2010-06-24	2013-02-21	Univ Indiana Res & Tech Corp	Profarmacos de peptido de la superfamilia de glucagon basado en amida.
ES2606554T3 (es)	2010-08-30	2017-03-24	Sanofi-Aventis Deutschland Gmbh	Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US20140045754A1 (en) *	2011-01-19	2014-02-13	Joern Drustrup	Glp-1 compositions
EP2694402B1 (en)	2011-04-01	2017-03-22	MannKind Corporation	Blister package for pharmaceutical cartridges
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
WO2012174472A1 (en)	2011-06-17	2012-12-20	Mannkind Corporation	High capacity diketopiperazine microparticles
US9950038B2 (en) *	2011-08-05	2018-04-24	The Trustees Of The Universiy Of Pennsylvania	Methods and compositions for inhibiting delayed graft function
PL2750699T3 (pl)	2011-08-29	2015-12-31	Sanofi Aventis Deutschland	Kombinacja farmaceutyczna do stosowania w kontroli glikemii u pacjentów z cukrzycą typu 2
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
HK1200318A1 (en)	2011-10-24	2015-08-07	曼金德公司	Methods and compositions for treating pain
HK1198810A1 (en)	2011-11-17	2015-06-12	Indiana University Research And Technology Corporation	Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
IN2014MN01887A (es) *	2012-03-01	2015-07-10	Yeda Res & Dev
EP2872205B1 (en)	2012-07-12	2017-02-08	MannKind Corporation	Dry powder drug delivery systems
US10159644B2 (en)	2012-10-26	2018-12-25	Mannkind Corporation	Inhalable vaccine compositions and methods
WO2014144895A1 (en)	2013-03-15	2014-09-18	Mannkind Corporation	Microcrystalline diketopiperazine compositions and methods
MX369511B (es)	2013-04-03	2019-11-11	Sanofi Sa	Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada.
KR102465025B1 (ko)	2013-07-18	2022-11-09	맨카인드 코포레이션	열-안정성 건조 분말 약제학적 조성물 및 방법
EP3030294B1 (en)	2013-08-05	2020-10-07	MannKind Corporation	Insufflation apparatus
US10307464B2 (en)	2014-03-28	2019-06-04	Mannkind Corporation	Use of ultrarapid acting insulin
US10561806B2 (en)	2014-10-02	2020-02-18	Mannkind Corporation	Mouthpiece cover for an inhaler
AU2015359376B2 (en)	2014-12-12	2021-09-09	Sanofi-Aventis Deutschland Gmbh	Insulin glargine/lixisenatide fixed ratio formulation
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
US10988737B2 (en) *	2015-04-28	2021-04-27	Universite De Strasbourg	Clinical gene signature-based human cell culture model and uses thereof
CN105504026B (zh) *	2015-12-24	2018-12-07	广东医科大学	一种pac1-r和glp-1r的双向激动剂ot23及应用
WO2017211321A1 (zh) *	2016-06-08	2017-12-14	上海交通大学医学院	增强激动型抗体活性的抗体重链恒定区序列
TWI829687B (zh)	2018-05-07	2024-01-21	丹麥商諾佛儂迪克股份有限公司	包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2021245199A1 (en)	2020-06-03	2021-12-09	Københavns Universitet	Glp1r agonist nmdar antagonist conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614492A (en) *	1986-05-05	1997-03-25	The General Hospital Corporation	Insulinotropic hormone GLP-1 (7-36) and uses thereof
ES2311560T3 (es) *	2000-12-07	2009-02-16	Eli Lilly And Company	Proteinas de fusion glp-1.
US20020187926A1 (en) *	2001-03-07	2002-12-12	Knudsen Liselotte Bjerre	Combined use of derivatives of GLP-1 analogs and PPAR ligands
BR0312276A (pt) *	2002-06-28	2005-04-26	Centocor Inc	Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
EA011583B1 (ru) *	2004-03-31	2009-04-28	Сентокор, Инк.	Миметические антитела glp-1 человека, композиции, способы и применения

2005
- 2005-12-22 US US11/315,728 patent/US20070128193A1/en not_active Abandoned
- 2005-12-22 BR BRPI0519241-2A patent/BRPI0519241A2/pt not_active Application Discontinuation
- 2005-12-22 EP EP05858658A patent/EP1843788A4/en not_active Withdrawn
- 2005-12-22 CA CA002592065A patent/CA2592065A1/en not_active Abandoned
- 2005-12-22 SG SG200908512-7A patent/SG158158A1/en unknown
- 2005-12-22 EA EA200701362A patent/EA200701362A1/ru unknown
- 2005-12-22 JP JP2007548473A patent/JP2008525477A/ja active Pending
- 2005-12-22 KR KR1020077016979A patent/KR20070090036A/ko not_active Withdrawn
- 2005-12-22 AU AU2005337493A patent/AU2005337493A1/en not_active Abandoned
- 2005-12-22 CN CNA2005800484969A patent/CN101415439A/zh active Pending
- 2005-12-22 WO PCT/US2005/046602 patent/WO2007046834A2/en not_active Ceased
- 2005-12-22 MX MX2007007602A patent/MX2007007602A/es not_active Application Discontinuation
2007
- 2007-06-14 IL IL183940A patent/IL183940A0/en unknown
- 2007-06-19 NI NI200700158A patent/NI200700158A/es unknown
- 2007-07-20 NO NO20073814A patent/NO20073814L/no not_active Application Discontinuation
- 2007-07-20 CR CR9266A patent/CR9266A/es not_active Application Discontinuation
- 2007-07-20 ZA ZA200706030A patent/ZA200706030B/xx unknown

Also Published As

Publication number	Publication date
EP1843788A4 (en)	2009-11-18
IL183940A0 (en)	2007-10-31
BRPI0519241A2 (pt)	2009-01-06
JP2008525477A (ja)	2008-07-17
ZA200706030B (en)	2009-12-30
WO2007046834A3 (en)	2009-06-18
NI200700158A (es)	2008-05-13
NO20073814L (no)	2007-09-14
EP1843788A2 (en)	2007-10-17
WO2007046834A2 (en)	2007-04-26
AU2005337493A1 (en)	2007-04-26
EA200701362A1 (ru)	2008-08-29
MX2007007602A (es)	2007-12-07
CA2592065A1 (en)	2007-04-26
KR20070090036A (ko)	2007-09-04
US20070128193A1 (en)	2007-06-07
CN101415439A (zh)	2009-04-22
SG158158A1 (en)	2010-01-29

Legal Events

Date	Code	Title	Description
2012-09-20	FA	Abandonment or withdrawal (granting procedure)

Publication	Publication Date	Title
CR8706A (es)	2009-01-16	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos, usos
CR10619A (es)	2009-06-04	Mimeticuerpos de peptido-1 similar a glucagon de humano, composiciones, metodos y usos
FR2900573B1 (fr)	2014-05-16	Nouvelles compositions cosmetiques renfermant au moins un peptide contenant au moins un cycle aromatique bloque
IL183940A0 (en)	2007-10-31	Glp-1 agonists, compositions, methods and uses
CR8642A (es)	2008-11-28	Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
PT1971366E (pt)	2014-11-06	Anticorpos humanos anti-il-23, composições, métodos e usos
TWI347313B (en)	2011-08-21	Novel substituted phenoxyacetic acids,pharmaceutical composition comprising them,and use thereof
ME01942B (me)	2015-05-20	Jedinjenja, preparati i metode
DK1888031T3 (da)	2013-02-18	GLP-1-analogformuleringer
FR2885904B1 (fr)	2007-07-06	Nouveaux derives du fluorene, compositions les contenant et utilisation
DE602005005587D1 (de)	2008-05-08	Haarkosmetische Zusammensetzung
BRPI0719497A2 (pt)	2014-02-18	"composição, processo de preparação de uma composição, usos de uma composição e uso coméstico de uma composição"
DE602005027899D1 (de)	2011-06-16	Mundpflegezusammensetzung mit dem extrakt von unoxidierter kamelie
DK2158281T3 (da)	2013-10-14	Farvepigmenteret laksammensætning med høj dækkeevne, forøget ridsefasthed, og let-at-rengøre egenskaber
ITMI20020189A0 (it)	2002-02-01	Composizione per uso farmaceutico o dietetico per contrastare la caduta dei capelli
DE602005012006D1 (de)	2009-02-12	Haarkosmetische Zusammensetzung
DE602005021571D1 (de)	2010-07-15	Haarkosmetische Zusammensetzung
EP1683510A4 (en)	2010-02-17	COSMETIC COMPOSITION
DK1812120T3 (da)	2015-07-27	Hudbeskyttende, alkalinitetskontrollerende præparat og anvendelsen deraf
DK1784174T3 (da)	2012-12-10	Famaceutisk sammensætning omfattende gabapentin
IL186307A0 (en)	2008-01-20	Human glp-1 mimetibodies, compositions, methods and uses
FR2861290B1 (fr)	2006-02-10	Composition cosmetique thermogonflante.
FR2863874B1 (fr)	2006-03-17	Composition demaquillante
CL2004000184A1 (es)	2005-04-22	Forma polimorfa cristalina del monohidrato de 4-ciclopentilresorcinol, composicion farmaceutica y su uso para reducir la pigmentacion.
ITMI20040943A1 (it)	2004-08-11	Composizione farmaceutica cicatrizzante